Mycobacterium avium brain abscess at the initiation of highly active antiretroviral therapy.
Berger
P
P
Unité des Rickettsies CNRS UMR 6020, IFR 48, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille Cédex 05, France.
Lepidi
H
H
Drogoul-Vey
M P
MP
Poizot-Martin
I
I
Drancourt
M
M
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology*; D000328:Adult; D000900:Anti-Bacterial Agents; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D000995:Antitubercular Agents / Q000627:therapeutic use; D001922:Brain Abscess / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009162:Mycobacterium avium / Q000302:isolation & purification*; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis* / Q000188:drug therapy; D035583:Rare Diseases; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents